Prof Tim Walsh has been studying antimicrobial resistance (AMR) mechanisms for over 25 years and publishes regularly in Nature and Lancet journals. Notably, in his career he has discovered and named two of the most notorious antibiotic resistant genes – NDM-1 and MCR-1. His work also helped discover the mobile tigecycline gene (tetX variant).

He is director of BARNARDS, a Gates Foundation project on AMR, prospectively examining the burden of neonatal sepsis in Pakistan, India, Bangladesh, Rwanda, South Africa, Nigeria (Abuja and Kano) and Ethiopia. Follow up programs include assessing the risks of still-born infants and maternal care in sub-Sahara Africa, as well as assessing the impact of access to affordable antibiotics. Prof Walsh has led studies in Pakistan investigating the role of insects in post-surgical infections and the unfortunate global trade of colistin in agriculture. Walsh was PI of DETER-XDR-CHINA, a study examining the spread and burden of AMR in public health sectors and hospitals in 30 provinces in China. He was also PI of CUT-SEC, a One Health project in China and Thailand. In addition to the above, he heads up a Welcome Trust study examining the international impact of COVID on AMR.

In 2020 Prof Walsh moved to University of Oxford and co-established the Ineos Oxford Institute of Antimicrobial Research, where he is Director of Biology. As part of the Institute, the Walsh Lab’s key interests are:

1. The use of antimicrobials in animals and its impact on human clinical failures.
2. The drivers of AMR across all One Health sectors.
3. Causes and management of AMR neonatal sepsis and stillbirths in low- and- middle income countries (LMICs)
4. The clinical and economic burden of AMR in LMICs.

Prof Walsh has also been appointed to the Fleming Fund expert advisory panel, is an advisor to the Foundation Merieux AMR teaching program, and is a member of the WHO Strategic and Technical Advisory Group for Antimicrobial Resistance (STAG-AMR).

Prof Walsh holds an honorary chair at the China Agricultural University in veterinary microbiology and is advisor to the ENABLE 2 program on antibacterial drug discovery. In 2020, he was awarded an OBE for his services to Microbiology and International Development, and in 2022 was awarded his DSc (University of Bristol).